Wednesday, January 25, 2012
ChemoCentryx Inc., of Mountain View, Calif., set a price range for its proposed initial public offering, in which it aims to sell 4 million shares priced between $14 and $16. At the midpoint, the offering would bring in $60 million in gross proceeds. ChemoCentryx filed an S-1 last year, hoping to raise about $69 million to support multiple clinical programs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.